Role of vascular endothelial growth factor in protein loss of Ménétrier's disease

TEIKO TAKEDA, KEIICHI MITSUYAMA, OSAMU TSURUTA, SHINICHI KUBOYAMA, SHIGEHIKO KITAZAKI and MICHIO SATA

Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Asahi-machi 67, Kurume 830-0011, Japan

Received April 10, 2006; Accepted June 13, 2006

Abstract. Vascular endothelial growth factor (VEGF) promotes protein leakage from blood vessels and endothelial cell growth. The expression of transforming growth factor (TGF)-α and its receptor is increased in the gastric mucosa of patients with Ménétrier’s disease. Since TGF-α stimulates the expression of VEGF mRNA in cultured keratinocytes, we hypothesized that VEGF may play an important role in the protein leakage of Ménétrier’s disease. Immunohistochemistry was performed using specific antibodies against VEGF and CD31 in gastric tissue specimens from 7 patients with Ménétrier’s disease and 10 controls. The effect of recombinant TGF-α on VEGF production by cultured lamina propria mononuclear cells (LPMCs) was assessed. VEGF expression was detected for LPMCs and occasional epithelial cells of the gastric mucosa of Ménétrier’s patients. VEGF-positive LPMCs were increased in tissues from patients with Ménétrier’s disease (P<0.001). Of the LPMCs, T-lymphocytes and macrophages were the major sources of VEGF. CD31-positive blood vessels were increased in Ménétrier’s tissue (P<0.05). Recombinant TGF-α induced the production of VEGF in cultured LPMCs (P<0.05). In conclusion, the increased expression of VEGF, as a result of overproduction of TGF-α, may play a key role in the pathophysiology of Ménétrier’s disease.

Introduction

Ménétrier’s disease is an uncommon disorder of unknown etiology characterized by enlarged gastric folds with foveolar hyperplasia and cystic dilatation of gastric glands (1). Transgenic mice which overexpress transforming growth factor (TGF)-α develop hypertrophic gastropathy similar to that seen in patients with Ménétrier’s disease (2,3). The expression of both TGF-α and its receptor is increased in the gastric mucosa of patients with Ménétrier’s disease (3). These findings in Ménétrier’s patients and in the animal model indicate that TGF-α may be involved in the pathogenesis of Ménétrier’s disease. Hypoproteinemia caused by gastric protein leakage is a critical problem in patients with Ménétrier’s disease. However, the exact mechanism of protein leakage remains unknown though enhanced microvascular permeability (4), dilated lymphatics (5), and widened epithelial tight junctions (6) in the stomach of patients with Ménétrier’s disease have been noted. It has been recently reported that the blockade of the epidermal growth factor receptor is an effective therapy in Ménétrier’s patients with severe albumin loss (7).

Vascular permeability factor (VPF) was originally identified as a 34- to 42-kDa glycoprotein secreted by tumor cells (8). This molecule can induce a 50,000-fold greater vascular permeability-enhancing activity than histamine (9). VPF is also a selective endothelial cell growth factor (10), hence its additional name, vascular endothelial growth factor (VEGF) (11,12). Several factors have been shown to induce VPF/VEGF production in vitro (13,14). Of particular interest is a report by Detmar et al demonstrating marked induction of VEGF mRNA by TGF-α in cultured epidermal keratinocytes (15). These findings led us to speculate that VEGF may play a key role in the protein leakage from the stomach of patients with Ménétrier’s disease, and, if so, inhibition of VEGF action could be used to treat the hypoproteinemia seen in Ménétrier’s patients.

In the present study, we examine for the first time the role of VEGF in the pathophysiology of Ménétrier’s disease. These results provide insights into the mechanisms of gastric protein leakage seen in this disorder, and provide a useful framework for developing strategies for therapeutic intervention.

Materials and methods

Patients and sample collection. Seven patients with Ménétrier’s disease were included in this study. The diagnosis was based on characteristic endoscopic and radiological features of Ménétrier’s disease. All patients fulfilled the histological criteria for either massive foveolar hyperplasia or hypertrophic lymphocytic gastritis forms of Ménétrier’s disease (6,16-18). Table I summarizes the clinical characteristics and...
Table I. Clinical characteristics of patients with Ménétrier's disease.

<table>
<thead>
<tr>
<th>Age/sex</th>
<th>Gastric fundus involvement in antrum</th>
<th>Basal pH (pg/ml)</th>
<th>Serum gastrin (g/dl)</th>
<th>Serum albumin</th>
<th>Gastric CI α-ATc</th>
<th>99mTc-HASd</th>
<th>131I-PVP (%)</th>
<th>Histology</th>
</tr>
</thead>
<tbody>
<tr>
<td>68/M</td>
<td>+</td>
<td>2.4</td>
<td>ND</td>
<td>2.5</td>
<td>5.4</td>
<td>ND</td>
<td>ND</td>
<td>Lymphocytic gastritis</td>
</tr>
<tr>
<td>71/M</td>
<td>+</td>
<td>7.6</td>
<td>ND</td>
<td>3.0</td>
<td>10.9</td>
<td>ND</td>
<td>ND</td>
<td>Massive foveolar hyperplasia</td>
</tr>
<tr>
<td>58/F</td>
<td>+</td>
<td>6.0</td>
<td>230</td>
<td>1.6</td>
<td>31.5</td>
<td>positive</td>
<td>7.9</td>
<td>Massive foveolar hyperplasia</td>
</tr>
<tr>
<td>28/F</td>
<td>+</td>
<td>8.5</td>
<td>203</td>
<td>2.2</td>
<td>ND</td>
<td>positive</td>
<td>5.5</td>
<td>Massive foveolar hyperplasia</td>
</tr>
<tr>
<td>79/M</td>
<td>+</td>
<td>ND</td>
<td>450</td>
<td>3.3</td>
<td>ND</td>
<td>positive</td>
<td>ND</td>
<td>Massive foveolar hyperplasia</td>
</tr>
<tr>
<td>74/M</td>
<td>+</td>
<td>ND</td>
<td>140</td>
<td>2.8</td>
<td>ND</td>
<td>positive</td>
<td>ND</td>
<td>Massive foveolar hyperplasia</td>
</tr>
</tbody>
</table>

*Normal, 0-200 pg/ml. aNormal, 3.5-5.2 g/dl. bGastric clearance of α-antitrypsin; normal, 0-0.89 ml/h. c99mTc-labeled human serum albumin. d131I-labeled polyvinylpyrrolidone; normal, 0-1.5%. ND, not done.

Laboratory data of each patient. Protein leakage in the stomach was examined in the seven patients using the following established methods: gastric clearance of α-antitrypsin (19), three patients; 131I-labeled polyvinylpyrrolidone excretion over 4 days, two patients; and abdominal scintigraphy using 99mTc-labeled human serum albumin (20), four patients.

Mucosal biopsy specimens were obtained from the gastric body during gastroscopy. They were fixed in 10% formalin and embedded in paraffin. Control mucosal specimens were obtained from grossly and microscopically normal mucosa of patients who had undergone gastroscopy and biopsy for investigation of gastrointestinal symptoms, but where no abnormality was found.

This study was performed according to the Helsinki Declaration and was approved by the Medical Ethics Committee of Kurume University Hospital. Informed consent was obtained from each patient who agreed to participate in this study.

**Immunohistochemistry.** Immunohistochemical study was performed on 6-μm paraffin sections of gastric mucosa which were deparaffinized in xylene and rehydrated in graded ethanol solution. Endogenous peroxidase activity was blocked with 0.03% hydrogen peroxide and sodium azide (Dako, CA, USA) for 10 min, and washed with phosphate-buffered saline (PBS). The tissue sections were pretreated with serum-free protein blocking (Dako, CA) for 10 min, incubated overnight at 4°C with primary antibody, and washed with PBS. Monoclonal antibodies against human VEGF (2E1, 10 μg/ml; IBL, Gunma, Japan), T cell markers CD45RO (UCHL1, 1:100; Dako, Glostrup, Denmark) (21,22), macrophage markers CD68 (PG-M1, 1:100; Dako, Glostrup), B cell markers CD20 (L26, 1:100; Dako, Glostrup) and endothelial cell markers CD31 (JC/70A, 1:20; Dako, Glostrup) (23-25) were used as primary antibodies. The slides were then incubated with anti-mouse biotinylated immunoglobulins (Vectastain ABC Kit, CA) for 30 min, washed with PBS, incubated with avidin-biotinylated horseradish peroxidase complex for 30 min, and washed with PBS. The slides were then stained with diaminobenzidine tetrahydrochloride substrate at room temperature, rinsed in tap water for 2 min, counterstained with Harris’ hematoxylin, and dipped in saturated lithium carbonate solution for blueing. For morphometric analysis, each microscope slide was analyzed independently in a blind manner by two trained pathologists. After counting the number of VEGF-positive cells or CD31-positive blood vessels in random areas on each section, the mean cell density was calculated using a semiautomatic computerized imaging analyzer (Nikon, Tokyo, Japan).

**Isolation of lamina propria mononuclear cells and culture.** LPMCs of the stomach were isolated with slight modifications (26,27). Specimens were obtained from patients with gastric cancer during gastrectomy. The specimens were collected from the operating room within 5 min of removal. Each specimen was opened longitudinally along the greater curvature and rinsed with cold 0.9% saline. The non-cancerous mucosa of the gastric body was freed from the underlying submucosal connective tissue, and was removed in strips. The gastric mucosal specimens were placed in Hanks’ balanced salt solution without calcium and magnesium (CM-FHBSS) with 5% fetal calf serum (FCS) (Gibco, Grand Island, NY, USA) containing 1 mM ethylenediamine tetraacetic acid (Analar BDH Chemicals, Poole, UK) in a V-bottom container. The specimens were then agitated for 1 h at 37°C to remove the epithelial layer; the remaining specimens were washed with RPMI 1640. The specimens were treated with collagenase type I (120 U/ml Sigma Chemical, St. Louis, MO) for 3 h at 37°C with agitation. The cellular supernatant was then washed three times, and the number and viability of isolated LPMCs...
were determined using acridine orange and ethidium bromide. The percentage of viable cells in each specimen was consistently >85%. The cells (2x10^6/ml) were cultured with various concentrations of recombinant TGF-α (Genzyme, Cambridge, MA, USA) for 24 h at 37˚C in an atmosphere of 5% CO₂. The culture supernatant was collected, filtered through a 0.45-μm filter, and stored frozen until assayed for VEGF by enzyme-linked immunosorbent assay (ELISA) (28,29).

**ELISA for VEGF.** The level of VEGF in the culture supernatants was measured by a colorimetric ELISA with slight modifications (28,29). This assay employed an anti-human VEGF polyclonal antibody elicited in rabbits by immunizing recombinant VEGF₁₂₁ protein (Toagosei Chemical Industry, Tsukuba, Japan), which was prepared with glutathione-S-transferase gene fusion system (Pharmacia Biotech., Tokyo, Japan). Ninety-six-well microtiter plates (Combiplate EB, Labsystems, Helsinki, Finland) were coated with 5 μg/ml of the purified anti-VEGF antibody in 0.1 M NaCl and 0.25 M carbonate buffer (pH 9.5), 0.1 M NaCl, and 0.1% NaH₃. The samples (100 μl) and serially diluted VEGF were added to the wells and incubated for 1 h at 22˚C. After washing the wells, 100 μl of horseradish peroxidase-conjugated Fab of the anti-VEGF antibody was added and incubated for 1 h at 22˚C. The wells were washed, and then incubated with the enzyme substrate (o-phenylenediamine, Sigma Chemical) at 22˚C for 30 min. The absorbance of each sample was measured with a plate reader, and the VEGF content of each sample was estimated from the standard curve of VEGF₁₂₁. This ELISA reacts with all isoforms of VEGF.

**Statistical analysis.** Each value is expressed as the mean ± SEM unless otherwise stated. Statistical analysis was performed with Student’s t-test, Mann-Whitney U test and
Kruskal-Wallis test. A value of P<0.05 was considered significant.

Results

Immunohistochemistry of VEGF. The localization of VEGF in the gastric mucosa of patients with Ménétrier's disease was examined by immunohistochemical analysis. VEGF immunoreactivity was predominantly seen in LPMCs (Fig. 1). Examination of serial sections showed VEGF-positive LPMCs were localized in T-lymphocytes (Fig. 2A and D) and macrophages (Fig. 2B and E). No VEGF-positive cells were present in B-lymphocytes (Fig. 2C and F). A small number of epithelial cells also stained positive for VEGF. The number of VEGF-positive LPMCs in Ménétrier's tissue was significantly higher than those of controls (P<0.001) (Fig. 3A). The number of VEGF-positive epithelial cells in Ménétrier's tissue was comparable to those of controls (Fig. 3B).

Immunohistochemistry of blood vessels. CD31 was localized to various degrees in vascular endothelial cells of gastric tissue obtained from both Ménétrier's patients and controls. The number of CD31-positive blood vessels in Ménétrier's tissue was significantly higher than those of controls (P<0.05) (Fig. 4).

Effect of TGF-α on VEGF production. We also studied the effect of recombinant TGF-α on VEGF production using LPMCs. Culturing LPMCs with TGF-α significantly increased the production of VEGF (P<0.05) (Fig. 5).

Discussion

Hypoproteinemia which occurs as a result of protein-losing gastropathy is a critical problem in patients with Ménétrier's disease. Since the precise mechanism of the protein loss is still unknown, treatment has been aimed at attempting to allay symptoms although the outcome is uncertain. It has been suggested that VEGF acts selectively on vascular endothelial cells to induce the protein loss through vesculo-vacuolar organelles (30) and/or through expanded intracellular spaces (31). In the present study, we focused on the role of VEGF in Ménétrier's disease.

We first assessed the topographic distribution of VEGF in the gastric mucosa in patients with Ménétrier's disease. We found that VEGF expression in the gastric mucosa was largely restricted to LPMCs. Among LPMCs, VEGF is mainly produced by T-lymphocytes and macrophages. This finding
coincides with the results of previous studies on other disease states, where immunohistochemical staining or in situ hybridization (32,33) were used. The production of VEGF in T-lymphocytes is important since it has been shown that T-lymphocytes participate in the pathophysiology of Ménétrier’s disease (16). Of particular note is that the number of VEGF-positive LPMCs in the gastric tissue of patients with Menetrier’s disease is higher than that of controls. This suggests that the enhanced expression of VEGF may contribute to the gastric protein leakage associated with this disorder. Further study involving the quantitation of VEGF levels in gastric tissue by direct measurement, short-term ex-vivo culture and perfusion techniques would help support this observation. This is the first demonstration of VEGF over-expression in patients with Ménétrier’s disease.

In addition to its ability to enhance vascular permeability, VEGF is also a selective promoting factor of vascular endothelial cell growth. We therefore evaluated the vascular density in tissue obtained from patients with Ménétrier’s disease using CD31, which specifically recognizes vascular endothelial cells. On immunohistochemical analysis, we found a significant increase in the number of blood vessels in Ménétrier’s tissue. This finding is consistent with a previous angiographic study which found hypervascular changes in the stomach of patients with Ménétrier’s disease (34). Although several angiogenic factors, such as basic fibroblast growth factor (FGF), TGF-α, TGF-β, EGF and tumor necrosis factor (TNF)-α, have been identified, our findings strongly suggest that VEGF may contribute to angiogenesis in Ménétrier’s disease.

Kondo et al reported that the activity of tissue plasminogen activator in Ménétrier’s disease is enhanced, which increases gastric vascular permeability (4). It has been shown that VEGF induces tissue plasminogen activators in vitro (35). Therefore, this enhanced activity would partially be due to VEGF which is produced excessively in the gastric mucosa in patients with Ménétrier’s disease.

What induces the increased expression of VEGF in Ménétrier’s disease is unknown. A recent in vitro study using epidermal keratinocytes has reported that TGF-α is a potent inducer for VEGF (15). Since the overexpression of TGF-α mRNA and protein is seen in patients with Ménétrier’s disease (3), we examined whether TGF-α induces VEGF production in the stomach. We found that LPMCs isolated from the human stomach produced VEGF in the presence of TGF-α. At present, the concentration of TGF-α in the gastric mucosa of patients with Ménétrier’s disease is unknown. However, our data highly suggest that TGF-α in high doses could stimulate the production of VEGF from the cells present in the stomach. Although other stimulatory factors must be considered, these results suggest that TGF-α may play an important role in VEGF synthesis in Ménétrier’s disease.

In summary, LPMCs in the gastric mucosa of patients with Ménétrier’s disease overexpressed VEGF. Of the LPMCs, T-lymphocytes and macrophages were the major sources of VEGF. Also, TGF-α induced VEGF synthesis in LPMCs. Our results indicate that the increased expression of VEGF, as a result of the overproduction of TGF-α, may play a key role in the pathophysiology of Ménétrier’s disease. Inhibiting the action of VEGF will likely be used for the treatment of hypoproteinemia in this disease.

References


